Lead Product(s): IOA-244
Therapeutic Area: Oncology
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: INKEF Capital
Deal Size: $16.5 million Upfront Cash: Undisclosed
Deal Type: Series A Financing January 23, 2020
iOnctura will use the proceeds of the Series A to move its lead molecule IOA-244, a highly selective PI3KÎ´-inhibitor, into a Phase I trial in solid tumours and its second program, IOA-289, an ATX-inhibitor, through IND enabling studies.